BackGenerate Biomedicines Overview
Generate Biomedicines, Inc.

Generate Biomedicines Target Price

Analysts' average 12-month price target for Generate Biomedicines is $26.

Get informed when a big investor buys or sells

+ Follow

Share Price

$16.28

Average Target Price

$25.6757.7% upside

3 analysts in the last 4 months

High: $30 | Low: $22

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-28H.C. Wainwright$3084.3% upsideOpen
2026-05-14Morgan StanleySean Laaman$2235.1% upsideOpen
2026-05-08H.C. WainwrightMitchell Kapoor$2553.6% upsideOpen

Generate Biomedicines (GENB) FAQ

The latest target price for GENB is $26. Investors often review this figure alongside Generate Biomedicines's historical trend and sector peers before judging valuation or financial health.

Generate Biomedicines trades near $16.28 while the consensus target sits at $26 (57.7% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting GENB's target price ($26), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.